Morten Jung, Markedschef, Dansk Erhverv
Stine Nynne Larsen, Specialkonsulent, Erhvervsministeriet
Birgit Munck-Kampmann, Markedschef - Cirkulær Økonomi, Niras A/S
Michael Søgaard Jørgensen, Lektor Ph.d., AAU
Victoria Stone-Bjarup, Responsible Sourcing Programme Manager, Novo Nordisk A/S
Kasper Lindgaard, Kontorchef, Erhvervsministeriet
Kontorchef for life science enheden i Erhvervsministeriet fortæller om arbejdet med at sikre gode vilkår for bl.a. medicovirksomheder og om sektorens økonomiske fodaftryk i Danmark.
Mads Veggerby Lausten, Corporate Vice President, Business Area Europe North and Central, Novo Nordisk A/S
Life science driver vækst i dansk økonomi, og life science afføder danske arbejdspladser og investeringer. For at være med helt i front kræver det investeringer i det danske hjemmemarked, incitamenter og adgang til dygtige talenter.
Anette Steenberg, Director of Investment Promotion, Copenhagen Capacity
Copenhagen Capacity strengthens the Life Science cluster Medicon Valley by attracting foreign direct investments to our Eco-system.
How do we do it? Why is it a good thing?
Dr. Hans Schambye, CEO, Galecto Biotech
The Danish Life Science industry is a remarkable strong point for Denmark. The Danish life science export has increased from about 4% of the total export in the nineties to more than 16% today.
The sector provides solutions to patients all over the World. More than 50% of the global market for hearing aids are manufactured by Danish companies, while Denmark is the site of production for about half of all insulin sold in the world. Furthermore, the sector contributes DKK 21 billion annually in corporate and personal taxes, hence plays a key role for the Danish welfare state.
It is crucial that more life science startups are created and built in Denmark in order to continue this impressive trajectory. The Danish universities generate top class science, but way too little of this research is transformed into new companies. Further, promising companies are typically sold to foreign acquirers rather than developed into strong and independent export successes. This is to a large extent caused by poorer basic conditions for life science startups in Denmark compared to the surrounding countries. For instance, tax deductions for R&D expenses should be improved to make it attractive to invest in research in Denmark. Further, it is hard to attract risk capital because our capital gains tax is the second highest among the OECD countries. Improving the conditions for life science companies is a very good investment – it generates novel treatments and solutions that help people around the World and leads to strong returns through more well paid jobs, tax revenues and increased export.
Danmark skal udbygge sin position som global førende life science-nation ved at være forrest i den internationale konkurrence om at skabe optimale vilkår omkring sektoren. Tid for nye politiske prioriteringer og ambitioner for life science.
Trial Nation’s target is to put Denmark at the center of the global clinical trials map.
What do we do and why do we do it?
See the full program in danish here